Preclinical and clinical gene therapy for haemophilia.
The goal of all haemophilia therapy is to prevent bleeding and its associated complications. Replacement by factor concentrates can only ever be suboptimum, and efforts are being made to correct the genetic cause of the disorder. Haemophilia is an ideal candidate for gene therapy, as it is caused by mutations in a single gene. A number of vectors have been used in an attempt to obtain therapeutic levels of factor VIII and factor IX in animal models, with some success. A number of phase 1 clinical trials have been conducted, and, although connection of the bleeding disorder was neither complete nor long-lasting, they do offer hope for a permanent gene-therapy cure for the disease.
Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, 3000 Leuven, Belgium.
M K L
MK
Chuah
D
D
Collen
T
T
Vandendriessche
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002986:Clinical Trials as Topic; D005164:Factor IX / Q000235:genetics; D005169:Factor VIII / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006467:Hemophilia A / Q000235:genetics / Q000628:therapy*; D002836:Hemophilia B / Q000235:genetics / Q000628:therapy; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D008979:Moloney murine leukemia virus / Q000235:genetics
D005169:Factor VIII; D005164:Factor IX